

**2018-19 EMERGING THERAPIES FOR PBC, NASH ESLD AND HCC SEMINAR SERIES**

**Seattle, WA – December 8, 2018**

**Conference Location**      **Renaissance Seattle Hotel**      **Phone: (206) 583-0300**  
 515 Madison Street      <https://www.marriott.co.uk/hotels/maps/travel/seasm-renaissance-seattle-hotel>  
 Seattle, WA

**Parking at the Conference**      A reduced parking rate of \$15 for the day has been arranged for all seminar participants.  
 Please bring your ticket to the Seminar Registration Desk to pick up the discount voucher. Other downtown parking lots are also available.

**Driving Directions**      **From Interstate 5 – Northbound toward Seattle** Take exit 164A for Dearborn St toward James St/ Madison St 0.5 mi. Follow signs for Dearborn Street/Interstate 5 N 0.6 mi . Keep left at the fork, follow signs for I-5 N/Vancouver B C/Madison St/Convention Center 0.2 mi.. Keep right at the fork, follow signs for Madison St/Convention Pl and merge onto 7th Ave 0.3 mi. Turn left onto Madison Street and the Hotel will be on your left.

**Seminar Agenda and Syllabus Information**      Registration and breakfast begin at **7:30 a.m.** in the **Visions Ballroom on the 28<sup>th</sup> floor.** Please check signage for any last minute room changes.  
**The Emerging Therapies seminar is a paperless program.** The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

<b>7:30 am</b>	<b>Registration, Continental Breakfast &amp; View Exhibits</b>
<b>8:00 am</b>	<b>Opening Comments and Pre-Test</b>
<b>8:20 am</b>	<b>End Stage Liver Disease: Treatment, Managing Complications and Transplant</b> <ul style="list-style-type: none"> <li>• Staging, workup, and diagnosis of cirrhosis</li> <li>• Medical care of the patient with end stage liver disease</li> </ul> Liver Transplantation <ul style="list-style-type: none"> <li>• Listing criteria, MELD scores, Exceptions and the transplant process</li> </ul> <b>Case Study 1 – Cirrhosis and Encephalopathy</b>
<b>9:25 am</b>	<b>Hepatocellular Carcinoma (HCC)</b> <ul style="list-style-type: none"> <li>• Screening diagnostic serum assays and imaging tests</li> <li>• Diagnosis without histology</li> <li>• Treatment and management options: Ablation, TACE and Surgery</li> </ul>
<b>10:00 am</b>	<b>Break &amp; View Exhibits</b>
<b>10:15 am</b>	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• Current FDA-Approved Therapies</li> <li>• New chemotherapy regimens in development and testing</li> <li>• Immunotherapy as the new MoA for HCC</li> </ul> <b>Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma</b>
<b>11:00 am</b>	<b>Primary Sclerosing Cholangitis (PSC)</b> <ul style="list-style-type: none"> <li>• Epidemiology</li> <li>• Ursodiol and Antibiotic Treatments</li> <li>• Predicting outcomes and Improving Survival</li> </ul>

11:25 am	<b>New Treatments for PBC</b> <ul style="list-style-type: none"> <li>• Causes and Markers of PBC</li> <li>• Treatment management</li> <li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> </ul>
12:00 pm	<b>Hosted Luncheon and Educational Session</b> “LAL-D: Lysosomal Acid Lipase Deficiency- Implementing Rule-out testing in patients with elevated ALT and LDL-C
12:45 pm	<b>Coffee and Dessert &amp; View Exhibits</b>
1:00 pm	<b>The Best Use of Non-Invasive Imaging for Fibrosis Assessment</b> <ul style="list-style-type: none"> <li>• Technologies, Procedures and Outcomes</li> </ul>
1:30 pm	<b>NAFLD, LAL-D and NASH</b> <ul style="list-style-type: none"> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> <li>• Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease</li> </ul>
2:15 pm	<b>Break &amp; View Exhibits</b>
2:30 pm	<b>NASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>• Current therapies for NASH</li> <li>• Life style changes as a therapy</li> <li>• Drugs in clinical development for NASH</li> </ul> <b>Case Study 3 - NASH Diagnosis and Treatment</b>
3:30 pm	<b>Post-test and Wrap-Up</b> <ul style="list-style-type: none"> <li>• <b>Session adjourns at 3:45pm</b></li> </ul>

**Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

**Recording and Photography**

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

**Attendance Policies**

**Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**CME Information**

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 7.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1085. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>TM</sup> organizations accredited by ACCME.

---

**Your Seminar  
Faculty**



**KRIS V. KOWDLEY, M.D.**

Dr. Kowdley is internationally recognized as a clinician, educator and researcher in the area of liver disease and has presented his research on liver diseases at more than 135 national and international meetings and scientific symposia. He is the author of over 375 articles, book chapters, reviews and commentaries in this area and has been published in the *Annals of Internal Medicine*, *Archives of Surgery*, *Gastroenterology*, *Hepatology*, *American Journal of Physiology*, *New England Journal of Medicine*, and among other professional publications.

Dr. Kowdley has extensive experience in clinical trials in all areas of liver disease, ranging from hepatitis C, cholestatic liver disease, nonalcoholic steatohepatitis and hepatitis B.

He has been a principal investigator in several NIDDK-sponsored clinical trials in primary biliary cirrhosis, primary sclerosing cholangitis and is a member of executive committee of the nonalcoholic steatohepatitis clinical research network (NASH CRN).



**CHARLES LANDIS, M.D.**

Dr. Charles Landis is a gastroenterologist in Seattle, Washington and is affiliated with multiple hospitals in the area, including UW Medicine/Harborview Medical Center and University of Washington Medical Center.

He received his medical degree from State University of New York Downstate Medical Center College of Medicine and completed his residency in Internal Medicine and a GI Fellowship at Albert Einstein College of Medicine in New York.



**PAULA COX-NORTH, PhD, ARNP, NP-C**

Dr. Paula Cox was born and raised in Washington state. She graduated from Gonzaga University with a Bachelor of Science in Nursing degree and has worked in many clinical areas as a registered nurse over her 32-year career including gastroenterology, hepatology research, and clinical hepatology.

After practicing for many years as a registered nurse, Dr. Cox went on to pursue a Masters in Nursing and a PhD in Nursing from the University of Washington. As an advanced practice nurse, she has continued to work in general gastroenterology and hepatology. Her hepatology practice has been centered on caring for vulnerable and underserved populations, and she has been actively involved with the community in both helping establish linkage to care and educating patients and health care providers.

---